Introduction of Radiofrequency Denervation Tecnhology
Radiofrequency Denervation is a revolutionary treatment for patients suffering from chronic pain, aiming to improve patient outcomes, reduce long-term healthcare costs, and align with National Institute for Health and Care Excellence (NICE) guidance.
Chronic pain affects countless individuals across the UK, leading to reduced quality of life, economic burden, and strain on NHS resources. Radiofrequency Denervation has emerged as an effective treatment modality, offering significant pain relief and enhancing patient wellbeing. Polar Medical is a specialist supplier of radiofrequency technology to NHS hospitals nationwide, providing patients with state of the art pain managment across the UK.
The Need for Radiofrequency Denervation in Modern Healthcare
Ever increasing number of patients with chronic pain
Reduction of reliance on opioid medications and their associated risks
- A significant proportion of patients do not respond to conventional treatments and require alternative modalities
NICE Guidance
NICE has endorsed Radiofrequency Denervation for various pain locations, recognising its clinical efficacy and cost-effectiveness:
Lumbar: CG88
Cervical: IPG582
Sacroiliac Joint (SIJ): IPG489
Genicular: IPG638
Suprascapular: IPG640
Radiofrequency Denervation Equipment & Consumables
For the successful implementation of this treatment, the purchase of a Radiofrequency Denervation generator and the associated consumables is paramount. Given the specialty of the procedure and the need for state-of-the-art equipment, partnering with a reputable supplier is essential. Diros Technology is a renowned global leader in this domain, offering:
Cutting-edge Radiofrequency Denervation equipment, ensuring optimum results
Training and after-sales support
Competitive pricing and warranty services
Justification for Purchase
The justification for investing in Radiofrequency Denervation Technology is firmly grounded in several key factors. Firstly, its adoption directly aligns with the recommendations set forth by the National Institute for Health and Care Excellence (NICE), ensuring that our practices are in accordance with the highest industry standards. Additionally, the long-term cost savings are a compelling argument in favour of this technology. By significantly reducing hospital stays, minimizing complications, and diminishing the need for pain medications, we can not only enhance patient care but also achieve substantial financial efficiencies. Moreover, the implementation of this technology is poised to deliver improved patient outcomes, ultimately leading to an elevated reputation and trust in RUHB’s pain management capabilities. This investment not only ensures that we stay at the forefront of medical advancements but also positions us as a trusted provider of cutting-edge care for our patients.
Implementation Strategy
Phase 1: Procurement of the Radiofrequency Denervation generator and consumables from Diros Technology.
Phase 2: Staff training, led by Diros Technology and supplemented by in-house specialists.
Phase 3: Soft launch with select patients, gathering feedback and refining the process.
Phase 4: Full rollout, with ongoing monitoring and evaluation.
Financial Forecast
Initial Investment: Cost of Radiofrequency Denervation generator, consumables, and training.
Ongoing Costs: Consumables, maintenance, and staff salaries.
ROI: Savings from reduced hospitalisation, decreased medication, and improved patient outcomes. Expected ROI within 18-24 months post-implementation.